Domestic single-dose flu drug approved

China's top drug regulator announced on Friday that it has approved a domestically developed flu drug requiring only a single dose throughout the entire treatment course, offering a new solution for an illness that infects five to 10 percent of adults globally each year.

The first-in-class innovative drug has been authorized to treat adult patients with uncomplicated influenza A and B, excluding those at high risk of severe flu-related complications, according to a statement from the National Medical Products Administration.

The drug, named ZX-7101A in clinical trials, was developed by Zenshine, a pharmaceutical company in Nanjing, Jiangsu province.